Object:To observe the expression of SLC1A5 in GC and analyze its relation with the clinicopathological features and prognosis and of GC.
Method: 90 cases of advanced gastric cancer tissues were selected as experiment group, and corresponding paracancerous tissues were showed as control group. Immunohistochemistry were used to observe the protein expression levels of SLC1A5 in two groups. The expression of SLC1A5 in 90 cases of advanced gastric cancer and its adjacent tissues was detected by immunohistochemistry. The relationship between the expression of SLC1A5 and clinicopathological features, as well as prognosis of gastric cancer was analyzed. By using gene database, we also analyzed the expression level of SLC1A5 in gastric cancer tissues and adjacent tissues, and its relation with prognosis of GC.
Results: Compared to the control group, the expression level of SLC1A5 significantly increased in advanced GC (P<0.0001). Statistical analysis by using GSE database also confirmed that the expression level of SLC1A5 significantly increased in GC tissues compared to the paracancerous tissues (GSE 65801, P =0.0046; GSE 63809, P<0.0001; GSE 27342, P=0.0147). The expression level of SLC1A5 in gastric cancer tissues was correlated with tumor size (P<0.05), depth of invasion (P<0.01), lymph node metastasis (P<0.05), TNM stage (P<0.05) and Ki-67 index (P<0.01). It was not related to age, sex, tumor location and degree of differentiation. Overexpression of SLC1A5 in gastric cancer was associated with poor prognosis (overall survival rate, P = 0.0131; non-recurrence survival rate, P = 0.0293). Meanwhile, database analysis is also confirmed that higher expression level of SLC1A5 in GC is associated with poor prognosis, which can significantly shorten the overall survival time (GSE 14210, P=0.011, GSE 22377, P=0.0015), and the progression free survival time of GC patients (GSE 14210, P=0.0095; GSE 22377, P=0.0012).
Conclusion:SLC1A5 protein expression in GC tissue increased, and the expression of SLC1A5 is associated with tumor size, depth of invasion, lymph node metastasis, TNM stage in advanced GC. High expression of SLC1A5 is associated with poor prognosis in patients with gastric cancer. |